Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Prolor HGH Treatment Moves Forward

By Drug Discovery Trends Editor | August 29, 2012

Biotech drugmaker Prolor Biotech is conducting key clinical trials of a long-acting growth hormone. The company should start a late-stage clinical trial of the drug and report results from one mid-stage and one-late stage trial before the end of 2013.

Prolor develops longer-lasting versions of approved products. The company says its carboxyl terminal peptide technology can make drugs last longer in a patient’s bloodstream. It says its human growth hormone could be injected once a week or twice a month instead of daily, making the product more convenient for patients. Prolor said the product could be used as a long-term treatment for growth failure.

The human growth hormone drug is Prolor’s most advanced product. The Israeli company is also studying treatments for conditions including hemophilia atherosclerosis, and rheumatoid arthritis.

Prolor collaborated with Merck & Co. on a long-acting version of follicle-stimulating hormone, an injectable hormone that is used to increase the chances of pregnancy. The European Union approved the product in 2010, and Merck markets it under the name Elonva. The approval shows Prolor’s technology can be effective.

Date: August 29, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE